BH3 Profiling for Cancer Chemosensitivity Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly chemotherapy, are often inefficient due to a lack of personalized approaches, as existing biomarkers are mostly correlative rather than causal, and fail to predict drug efficacy in patients, leading to ineffective treatments.
Innovation Solution
A method involving BH3 profiling to determine cancer treatment effectiveness by assessing the mitochondrial membrane potential change in cancer cells exposed to BH3 domain peptides, combined with clinical factors like age and cytogenetic status, to predict chemosensitivity and clinical response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If BH3 profiling is used to measure mitochondrial membrane potential change, then predictive capacity for chemosensitivity is improved, but device complexity and assay sophistication increase
Solution Approach 1:
The patent replaces complex mechanical or chemical assays with a fluorescence-based optical detection system. BH3 domain peptides are used to probe mitochondrial membrane potential, and fluorescent dyes (such as JC-1 or TMRM) provide real-time, non-invasive measurement of membrane potential changes. This substitution of mechanical/chemical measurement with optical detection simplifies the assay while maintaining high predictive capacity for chemosensitivity.
Solution Approach 2:
The patent utilizes changes in fluorescence parameters (intensity, wavelength, polarization) to detect mitochondrial membrane potential changes. By monitoring fluorescence emission ratios or intensity changes in response to BH3 peptide treatment, the assay translates complex biochemical events into quantifiable optical signals, improving measurement precision without requiring complex device infrastructure.
2Reliability
If personalized medicine approach is implemented with precise diagnostics, then drug efficacy is improved, but time and resources for testing increase
Solution Approach 1:
The patent performs BH3 profiling and mitochondrial membrane potential assessment on tumor tissue samples obtained during diagnostic procedures (biopsies) before chemotherapy initiation. This preliminary testing establishes a baseline predictive marker for chemosensitivity, allowing clinicians to select the most effective chemotherapy regimen in advance, thereby improving drug efficacy while minimizing the time lost to treatment trials.
Solution Approach 2:
The patent uses in vitro cell cultures derived from patient tumor samples to perform BH3 profiling. These cell copies retain the genetic and biochemical characteristics of the original tumor, allowing predictive testing to be performed on cultured cells rather than requiring complex in vivo models or prolonged patient monitoring, thus reducing testing time while maintaining reliability.
3Ease of operation
If existing biomarkers are used for treatment selection, then ease of implementation is maintained, but predictive accuracy deteriorates
Solution Approach 1:
The patent replaces traditional immunohistochemistry or Western blotting methods for biomarker detection with fluorescence-based mitochondrial membrane potential measurement. This substitution maintains ease of implementation by using standard fluorescence microscopy or flow cytometry equipment already present in many laboratories, while simultaneously improving predictive accuracy by measuring functional mitochondrial status rather than static protein expression levels.
Solution Approach 2:
The patent shifts from measuring static biomarker parameters (protein expression levels) to dynamic functional parameters (mitochondrial membrane potential changes in response to BH3 peptides). This parameter change enables real-time assessment of chemosensitivity, improving predictive accuracy while maintaining operational simplicity through automated fluorescence reading systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach improves the predictive capacity for cancer treatment responses, allowing for more personalized and effective chemotherapy by identifying patient-specific BH3 profiles and clinical factors that correlate with treatment outcomes.
Implementation Method 1
determining a change in mitochondrial membrane potential upon contacting the permeabilized cells with one or more BH3 domain peptides
Implementation Method 2
AUC is either (i) the area under a curve of a homogenous time-resolved fluorescence (HTRF) measurement, or (ii) the mean signal intensity of a fluorescence activated cell sorting (FACS) measurement
Data Source
Figure 1
Figure 1
Figure 1
AI summary
The present invention relates to a method for determining a cancer treatment for a patient, comprising: determining a BH3 profile for the patient's tumor or cancer cell specimen; determining one or more clinical factors of the patient, and classifying the patient for likelihood of clinical response to one or more cancer treatments; wherein the one or more clinical factors are selected to increase specificity and/or sensitivity of the BH3 profile for association with clinical response.